Adoptive immunotherapy for advanced non-small celllung cancer using zoledronate-expanded γδT cells: APhase i clinical study

Journal of Immunotherapy

Volumn 34, Issue 2, 2011, Pages 202-211

  Sakamoto, Miki ^a   Nakajima, Jun ^a   Murakawa, Tomohiro ^a   Fukami, Takeshi ^a   Yoshida, Yukihiro ^a   Murayama, Tomonori ^a   Takamoto, Shinichi ^a   Matsushita, Hirokazu ^a   Kakimi, Kazuhiro ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

T cell; immunotherapy; zoledronate

Indexed keywords

INTERLEUKIN 2; ZOLEDRONIC ACID;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CELL EXPANSION; CELL STIMULATION; CLINICAL ARTICLE; FEMALE; GAMMA DELTA T LYMPHOCYTE; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SAFETY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 79953065783     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318207ecfb     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108. (Pubitemid 40372904)
2. Asamura H, Goya T, Koshiishi Y, et al. A Japanese lung cancer registry study: prognosis of 13,010 resected lung cancers. J Thorac Oncol. 2008;3:46-52.
3. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552-3559.
4. Sugimura H, Nichols FC, Yang P, et al. Survival after recurrent non-small-cell lung cancer after complete pulmonary resection. Ann Thorac Surg. 2007;83:409-417.
5. Ohe Y, Ishizuka N, Tamura T, et al. Long-term follow-up of patients with unresectable locally advanced non-small cell lung cancer treated with chemoradiotherapy: a retrospective analysis of the data from the Japan Clinical Oncology Group trials (JCOG0003A). Cancer Sci. 2003;94:729-734. (Pubitemid 37160932)
6. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: four-arm cooperative study in Japan. Ann Oncol. 2007;18:317-323. (Pubitemid 46323100)
7. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ. 1995;311:899-909.
8. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59:225-249.
9. Kakimi K, Nakajima J, Wada H. Active specific immunother-apy and cell-transfer therapy for the treatment of non-small cell lung cancer. Lung Cancer. 2009;65:1-8.
10. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopula-tion with antitumor lymphocytes. Science. 2002;298:850-854. (Pubitemid 35231542)
11. Hayday AC. gd cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000; 18:975-1026. (Pubitemid 30365402)
12. Carding SR, Egan PJ. gd T cells: functional plasticity and heterogeneity. Nat Rev Immunol. 2002;2:336-345.
13. Triebel F, Hercend T. Subpopulations of human peripheral T gd lymphocytes. Immunol Today. 1989;10:186-188.
14. Bonneville M, Scotet E. Human Vg9Vd 2 T cells: promising new leads for immunotherapy of infections and tumors. Curr Opin Immunol. 2006;18:539-546. (Pubitemid 44311448)
15. Bennouna J, Bompas E, Neidhardt EM, et al. Phase-I study of Innacell gd: an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2008;57:1599-1609.
16. Kobayashi H, Tanaka Y, Yagi J, et al. Safety profile and anti-tumor effects of adoptive immunotherapy using gd T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother. 2007;56:469-476. (Pubitemid 46204533)
17. Kondo M, Sakuta K, Noguchi A, et al. Zoledronate facilitates large-scale ex vivo expansion of functional gd T cells from cancer patients for use in adoptive immunotherapy. Cytother-apy. 2008;10:842-856.
18. Sato K, Kondo M, Sakuta K, et al. Impact of culture medium on the expansion of T cells for immunotherapy. Cytotherapy. 2009;11:936-946.
19. Nakajima J, Murakawa T, Fukami T, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gd T cells. Eur J Cardiothorac Surg. 2010;37:1191-1197.
20. Wang XM, Terasaki PI, Rankin GW Jr, et al. A new microcellular cytotoxicity test based on calcein AM release. Hum Immunol. 1993;37:264-270. (Pubitemid 23343716)
21. Sasawatari S, Tadaki T, Isogai M, et al. Efficient priming and expansion of antigen-specific CD8+ T cells by a novel cell-based artificial APC. Immunol Cell Biol. 2006;84: 512-521. (Pubitemid 44657023)
22. Gober HJ, Kistowska M, Angman L, et al. Human T-cell receptor gd cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med. 2003;197:163-168. (Pubitemid 36152311)
23. Kunzmann V, Bauer E, Wilhelm M. gd T-cell stimulation by pamidronate. N Engl J Med. 1999;340:737-738.
24. Wilhelm M, Kunzmann V, Eckstein S, et al. gd T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102:200-206. (Pubitemid 36759655)
25. Dieli F, Vermijlen D, Fulfaro F, et al. Targeting human gd T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 2007;67: 7450-7457. (Pubitemid 47206575)
26. Caccamo N, Meraviglia S, Ferlazzo V, et al. Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vg9Vd2 naive, memory and effector T-cell subsets. Eur J Immunol. 2005;35:1764-1772. (Pubitemid 40862324)
27. Baccala R, Witherden D, Gonzalez-Quintial R, et al. gd T-cell homeostasis is controlled by IL-7 and IL-15 together with subset-specific factors. J Immunol. 2005;174:4606-4612.
28. Viey E, Lucas C, Romagne F, et al. Chemokine receptors expression and migration potential of tumor-infiltrating and peripheral-expanded Vg9Vd2 T Cells from renal cell carcinoma patients. J Immunother. 2008;31:313-323. (Pubitemid 351441003)
29. Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419:734-738. (Pubitemid 35177960)
30. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol. 2008;26:4244-4252.